<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113130</article-id><article-id pub-id-type="publisher-id">ACM-40833</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_38250893.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  非增殖性糖尿病视网膜病变的治疗现状
  The Current Situation of Treatment for Non-Proliferative Diabetic Retinopathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邵</surname><given-names>婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>理论</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>延安大学附属医院眼科，陕西 延安</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>907</fpage><lpage>911</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    随着人口老龄化、城市化进展迅速，不平衡的饮食搭配、突出的三高问题、肥胖、遗传等诸多因素导致2型糖尿病成为当代社会人类健康最大威胁之一，而微血管病变所带来的慢性并发症糖尿病视网膜病变(diabetic retinopathy, DR)患病率也逐渐升高，DR是糖尿病患者群体主要致盲疾病之一，根据进展程度及视网膜病变表现分为非增殖性糖尿病视网膜病变(non-proliferative diabetic retinopathy, NPDR)及增殖性糖尿病视网膜病变(proliferative diabetic retinopathy, PDR)。长久以来，对PDR治疗的研究较为透彻，而NPDR的治疗方式不尽详细。本文收集近几年国内外关于非NPDR的治疗方式，旨在增进临床医生对该病的了解，更有效地延缓糖尿病视网膜病变进展，提高患者生活质量。
    With the rapid development of population aging and urbanization, type 2 diabetes has become one of the greatest threats to human health due to many factors, such as unbalanced diet, prominent three high problems, obesity, genetics and so on. DR is one of the main blinding diseases in diabetic patients. According to the degree of progression and retinopathy, DR can be divided into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). For a long time, the research on the treatment of PDR is more thorough, but the treatment of NPDR is not detailed. This paper collects the treatment methods of NPDR at home and abroad in recent years, aiming to improve the understanding of the disease among clinicians, delay the progress of diabetic retinopathy more effectively, and improve the quality of life of patients. 
  
 
</p></abstract><kwd-group><kwd>非增殖期糖尿病视网膜病变，治疗，现状, Non-Proliferative Diabetic Retinopathy</kwd><kwd> Treatment</kwd><kwd> Current Situation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>随着人口老龄化、城市化进展迅速，不平衡的饮食搭配、突出的三高问题、肥胖、遗传等诸多因素导致2型糖尿病成为当代社会人类健康最大威胁之一，而微血管病变所带来的慢性并发症糖尿病视网膜病变(diabetic retinopathy, DR)患病率也逐渐升高，DR是糖尿病患者群体主要致盲疾病之一，根据进展程度及视网膜病变表现分为非增殖性糖尿病视网膜病变(non-proliferative diabetic retinopathy, NPDR)及增殖性糖尿病视网膜病变(proliferative diabetic retinopathy, PDR)。长久以来，对PDR治疗的研究较为透彻，而NPDR的治疗方式不尽详细。本文收集近几年国内外关于非NPDR的治疗方式，旨在增进临床医生对该病的了解，更有效地延缓糖尿病视网膜病变进展，提高患者生活质量。</p></sec><sec id="s2"><title>关键词</title><p>非增殖期糖尿病视网膜病变，治疗，现状</p></sec><sec id="s3"><title>The Current Situation of Treatment for Non-Proliferative Diabetic Retinopathy<sup> </sup></title><p>Ting Shao<sup>1</sup>, Lilun Wang<sup>2</sup>, Yan Gao<sup>1</sup></p><p><sup>1</sup>Yan’an University, Yan’an Shaanxi</p><p><sup>2</sup>Department of Ophthalmology, Yan'an University Affiliated Hospital, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/13-1571992x4_hanspub.png" /></p><p>Received: Feb. 8<sup>th</sup>, 2021; accepted: Feb. 28<sup>th</sup>, 2021; published: Mar. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/13-1571992x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>With the rapid development of population aging and urbanization, type 2 diabetes has become one of the greatest threats to human health due to many factors, such as unbalanced diet, prominent three high problems, obesity, genetics and so on. DR is one of the main blinding diseases in diabetic patients. According to the degree of progression and retinopathy, DR can be divided into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). For a long time, the research on the treatment of PDR is more thorough, but the treatment of NPDR is not detailed. This paper collects the treatment methods of NPDR at home and abroad in recent years, aiming to improve the understanding of the disease among clinicians, delay the progress of diabetic retinopathy more effectively, and improve the quality of life of patients.</p><p>Keywords:Non-Proliferative Diabetic Retinopathy, Treatment, Current Situation</p><disp-formula id="hanspub.40833-formula9"><graphic xlink:href="//html.hanspub.org/file/13-1571992x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-1571992x7_hanspub.png" /> <img src="//html.hanspub.org/file/13-1571992x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>非增殖性糖尿病视网膜病变(NPDR)是DR的一个发展进程，其眼底表现主要为微动脉瘤、出血点、软性渗出及硬性渗出，此阶段即可引起患者视力下降、视物模糊等症状。相较于PDR阶段，NPDR对视力的影响程度较小，但正因如此，不易引起患者的重视，不能进行及时的治疗及干预，导致NPDR逐步发展为PDR，严重影响患者视力及预后。故早期的健康教育及相关的药物治疗措施在延缓DR进展方面尤为重要。</p></sec><sec id="s6"><title>2. 健康教育</title><sec id="s6_1"><title>2.1. 心理辅助</title><p>降血糖及维持血糖平稳是DR患者的长期目标，而控制血糖需要终生用药，严格控制饮食、定时监测血糖变化，保持健康的方式。处于健康不平等状态，长期控制血糖的过程中，患者容易产生焦虑，抑郁等负面情绪，从而影响工作生活 [<xref ref-type="bibr" rid="hanspub.40833-ref1">1</xref>]，不愿按时定量服药，不配合医生治疗，不利于疾病预后。有研究表明 [<xref ref-type="bibr" rid="hanspub.40833-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40833-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40833-ref4">4</xref>]，有效的心理疏导，及时给予心理支持，能缓解糖尿病患者紧张、抑郁心情，保证患者能做到长期坚持，更好的配合治疗。故对于NPDR患者，应定期随访，予以社会心理论支持，家属及时疏导负面情绪，给与支持关怀。</p></sec><sec id="s6_2"><title>2.2. 生活指导</title><p>对于DR患者，除胰岛素或降糖药外，良好的生活习惯也不可或缺。</p><sec id="s6_2_1"><title>2.2.1. 个性化健康档案</title><p>建立个人医疗档案，内容涵盖一般个人资料，如性别、年龄、职业、不良嗜好等；疾病资料应涵盖糖尿病分型、病程、治疗经过、并发症、全身状况、糖化血红蛋白、用药及用量情况、血糖表、眼底造影结果、DR分型分级等；健康档案可帮助医生及患者了解病情进展及控制情况，提醒患者按时复查，及时发现病情变化 [<xref ref-type="bibr" rid="hanspub.40833-ref5">5</xref>]。</p></sec><sec id="s6_2_2"><title>2.2.2. 饮食及运动指导</title><p>以知识讲座方式对DR患者开展教育，帮助患者建立科学的饮食结构，提高饮食均衡性、尤其是蛋白质、碳水化合物及纤维素的摄入量配比。帮助患者选择合适的运动加入到治疗方案中、戒掉不良嗜好、建立自我管理意识 [<xref ref-type="bibr" rid="hanspub.40833-ref6">6</xref>]。</p></sec></sec></sec><sec id="s7"><title>3. 药物治疗</title><sec id="s7_1"><title>3.1. 复方樟柳碱</title><p>复方樟柳碱是复合生物碱，其效应机制类似于阿托品类药物，作用：1) 抗胆碱能作用：松弛血管平滑肌、散大瞳孔、抑制唾液腺等腺体分泌、解除微血管痉挛；2) 调节脉络膜植物神经功能，保持脉络膜正常的血管舒缩活动，改善眼部血流循环；3) 抗自由基、抗炎、抑制纤维增，减轻炎症损伤；4) 修护管壁内皮细胞，维护血管壁的正常通透性。其主要作用即为改善眼部血液供应情况，促进出血、水肿、渗出的吸收 [<xref ref-type="bibr" rid="hanspub.40833-ref7">7</xref>]。樟柳碱是目前治疗轻中度DR安全有效治疗方法之一，但研究中发现复方樟柳碱虽然可以促进眼底视网膜小点片状出血的吸收，但对视网膜初期病变如微血管瘤的作用有限且对视力的提升效果并不显著 [<xref ref-type="bibr" rid="hanspub.40833-ref8">8</xref>]。</p></sec><sec id="s7_2"><title>3.2. 醛糖还原酶抑制剂</title><p>醛糖还原酶是多元醇途径的限速酶，正常情况，细胞内葡萄糖参与糖酵解途径为机体供能，但糖尿病患者血糖高，激活多元醇途径，多余的葡萄糖在醛糖还原酶及山梨糖醇脱氢酶的作用下生成果糖 [<xref ref-type="bibr" rid="hanspub.40833-ref9">9</xref>]。烟酰胺腺嘌呤二核苷酸磷酸(NADPH)及烟酰胺腺嘌呤二核苷酸(NAD+)被利用消耗，导致抗氧化剂谷胱甘肽(GSH)减少，而活性氧自由基(ROS)蓄积，从而引发氧化应激 [<xref ref-type="bibr" rid="hanspub.40833-ref10">10</xref>]。醛糖还原酶DR发展过程中的一个重要节点，故其抑制剂可作为靶点去干预DR发展，目前依帕司已经应用于临床并有了一定的疗效，这与其抗氧化作用及减轻炎症有关 [<xref ref-type="bibr" rid="hanspub.40833-ref11">11</xref>]。</p></sec><sec id="s7_3"><title>3.3. 胰岛素治疗</title><p>有研究表明，相较于单纯口服降糖药患者，NPDR接受胰岛素强化治疗可保护视网膜神经细胞，有效改善视神经状态。国外学者研究给构造糖尿病大鼠模型注射胰岛素，在恢复了视网膜胰岛素受体的活性后也发现通过调节生长因子和炎症通路，胰岛素具有保护视网膜神经细胞的作用。但关于胰岛素对神经细胞保护作用相关文献不足，且临床应用研究缺乏 [<xref ref-type="bibr" rid="hanspub.40833-ref12">12</xref>]。</p></sec><sec id="s7_4"><title>3.4. 中药治疗</title><p>近年来，中药在NPDR的治疗中发挥了重要作用，现有药物如复方血栓通胶囊、盐酸川芎嗪、复方丹参滴丸、化瘀明目合剂、清热化瘀方等 [<xref ref-type="bibr" rid="hanspub.40833-ref13">13</xref>]。其主要作用不尽相同，多为改善微血管循环、促进出血及渗出液吸收、降低血液黏度等 [<xref ref-type="bibr" rid="hanspub.40833-ref14">14</xref>]。国内相关研究表明，NPDR患者单独或联合应用中药可减少微动脉瘤，减轻网膜出血及渗出，消黄斑水肿，提高网膜抗氧化应激能力，对患者视力有一定提升作用 [<xref ref-type="bibr" rid="hanspub.40833-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.40833-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40833-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40833-ref18">18</xref>]。</p></sec><sec id="s7_5"><title>3.5. 神经营养因子</title><p>神经营养因子在神经元的发育、存活和凋亡各时期有调节作用，脑源性生长因子(BDNF)便是其中之一。支持、营养、保护感光细胞及各级神经元细胞的Muller细胞是网膜神经胶质细胞 [<xref ref-type="bibr" rid="hanspub.40833-ref19">19</xref>]，Muller细胞摄取细胞的外代谢生成的谷氨酸，谷氨酸是神经元之间的神经递质，通过细胞中的谷氨酰胺合成酶将其转化为谷氨酰胺。DR患者Muller细胞作用减弱，致使谷氨酸在细胞外堆积，经过一系列反应诱导了神经细胞凋亡的发生。</p><p>BDNF可增加Muller细胞对谷氨酸敏感性，摄入增多，减少细胞外堆积，减轻其兴奋性毒性作用，对神经节细胞具有抗氧化应激作用 [<xref ref-type="bibr" rid="hanspub.40833-ref20">20</xref>]。临床上现已应用鼠神经生长因子肌肉注射治疗DR患者，且临床证明早期应用神经营养因子效用优于晚期使用。</p></sec></sec><sec id="s8"><title>4. 激光治疗</title><p>激光治疗是目前DR有效治疗措施，作用机制：1) 利用激光热效应损伤正常外层视网膜结构，减少其代谢及耗氧量，供给内层视网膜；2) 视网膜变薄，脉络氧气供应内层；3) 收缩小动脉、小静脉及毛细血管，减少血管的渗漏；4) 封闭无灌注区，控制新生血管生长因子(VEGF)生成 [<xref ref-type="bibr" rid="hanspub.40833-ref21">21</xref>]。视网膜激光光凝术(PRP)简而言之是弃车保帅，破坏正常外层网膜结构，现阶段轻、中度的NPDR的患者并不推行PRP治疗，过度损伤正常网膜反而会引起视功能的下降。但有部分研究采用直径200~300 μm的较小的光斑对轻中度患者进行轻度播散全视网膜激光光凝，发现这样的光凝方式及实际对于轻中度DR患者周边视野影响较小，控制进展的同时也可维持现有视力水平 [<xref ref-type="bibr" rid="hanspub.40833-ref22">22</xref>]。</p></sec><sec id="s9"><title>5. 总结</title><p>按照DR的严重程度，临床上根据眼底视网膜表现将DR分为NPDR及PDR，PDR致盲风险较高，治疗较为复杂，激光为破坏性手术，部分患者需要重复多次激光治疗，玻璃体牵拉性视网膜脱离等增殖性DR患者往往需要手术治疗，视力预后相较于NPDR患者较差，且治疗费用增加，激光及手术治疗改善视力的作用并不显著，故DR的治疗重点不仅在于解决已经发生的新生血管，出血，黄斑水肿，甚至是视网膜脱离，延缓控制NPDR向PDR的发展显得更为重要，尤其是现今社会人们对生活的质量的要求日益增高，对视力恢复的要求也较高，除控制糖尿病发展外，寻求新的治疗方案延缓DR进展，提高患者生活体验也应该引起重视。</p></sec><sec id="s10"><title>文章引用</title><p>邵 婷,王理论,高 燕. 非增殖性糖尿病视网膜病变的治疗现状The Current Situation of Treatment for Non-Proliferative Diabetic Retinopathy[J]. 临床医学进展, 2021, 11(03): 907-911. https://doi.org/10.12677/ACM.2021.113130</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40833-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">赵晓航, 阮航清. 中国成年人抑郁症状的社会经济梯度研究——基于“中国家庭追踪调查”2014年和2016年数据[J]. 北京社会科学, 2019(8): 34-47.</mixed-citation></ref><ref id="hanspub.40833-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志, 2018, 38(4): 292-344.</mixed-citation></ref><ref id="hanspub.40833-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">郭体宇. 健康教育联合心理护理干预对老年糖尿病患者心理情绪自我管理以及生活质量的影响[J]. 中国药物与临床, 2020, 20(16): 2798-2800.</mixed-citation></ref><ref id="hanspub.40833-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kane, N.S., Hoogendoorn, C.J., Tanenbaum, M.L., et al. (2018) Physical Symptom Complaints, Cognitive Emotion Regulation Strategies, Self-Compassion and Diabetes Distress among Adults with Type 2 Diabetes. Diabetic Medicine, 35, 1671-1677.</mixed-citation></ref><ref id="hanspub.40833-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杜娜娜, 陈方方. 健康教育临床护理路径应用于糖尿病临床护理中的效果[J]. 中国当代医药, 2020, 27(35): 246-248+252.</mixed-citation></ref><ref id="hanspub.40833-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Davis, P., Clarkson, J., Henry, C., et al. (2008) Interprofessional Continuing Health Education for Diabetic Patients in an Urban Underserved Community. Journal of Interprofessional Care, 22, 51-60.  
&lt;br&gt;https://doi.org/10.1080/13561820802013115</mixed-citation></ref><ref id="hanspub.40833-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">徐琪, 赵秀丽. 复方樟柳碱注射液在眼科的临床应用研究进展[J]. 中国临床药理学杂志, 2017, 33(9): 861-864.</mixed-citation></ref><ref id="hanspub.40833-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">闫海艳, 孙威. 复方樟柳碱治疗轻中度非增殖期糖尿病视网膜病变的临床观察[J]. 中国医药指南, 2017, 15(13): 97-98.</mixed-citation></ref><ref id="hanspub.40833-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">何媛, 周涛, 苏婷, 李海涛, 张海林. 糖尿病视网膜病变的分类、发生机制及治疗进展[J]. 山东医药, 2020, 60(19): 111-115.</mixed-citation></ref><ref id="hanspub.40833-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Peng, J.J., Xiong, S.Q., Ding, L.X., et al. (2019) Diabetic Retinopathy: Focus on NADPH Oxidase and Its Potential as Therapeutic Target. European Journal of Pharmacology, 15, 381-387. &lt;br&gt;https://doi.org/10.1016/j.ejphar.2019.04.038</mixed-citation></ref><ref id="hanspub.40833-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">高瑞, 付金京, 吴护群, 孔德博. 依帕司他联合西洛他唑治疗DR的疗效及机制研究[J]. 西南国防医药, 2019, 29(3): 368-370.</mixed-citation></ref><ref id="hanspub.40833-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fort, P.E., Losiewicz, M.K., Reiter, C.E., et al. (2011) Differential Roles of Hyperglycemia and Hypoinsulinemia in Diabetes Induced Retinal Cell Death: Evidence for Retinal Insulin Resistance. PLoS ONE, 6, e26498.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0026498</mixed-citation></ref><ref id="hanspub.40833-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">李春敏. 清热化瘀方治疗非增殖期糖尿病视网膜病变的临床观察[J]. 国际眼科杂志, 2019, 19(1): 148-150.</mixed-citation></ref><ref id="hanspub.40833-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">李佳, 王金萍, 忻晓晶, 刘芳. 非增殖期糖尿病视网膜病变的药物治疗进展[J]. 内蒙古中医药, 2020, 39(3): 164-165.</mixed-citation></ref><ref id="hanspub.40833-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">戴国令, 顾艳芳. 芪明颗粒治疗非增殖期糖尿病视网膜病变疗效观察[J]. 糖尿病新世界, 2018, 21(1): 185-186.</mixed-citation></ref><ref id="hanspub.40833-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">尹成玉, 宁美真, 崔海萍, 叶芳. 丹参多酚酸盐联合羟苯磺酸钙治疗非增殖性糖尿病视网膜病变的疗效观察[J]. 中国临床医生杂志, 2020, 48(9): 1035-1037.</mixed-citation></ref><ref id="hanspub.40833-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">时姣. 大剂量川芎嗪应用于非增殖期糖尿病视网膜病变的效果及对血流动力学影响[J]. 医学理论与实践, 2020, 33(20): 3419-3420.</mixed-citation></ref><ref id="hanspub.40833-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">刘鸫, 周群, 张豫临. 复方血栓通联合羟苯黄酸钙治疗非增殖期糖尿病视网膜病变对HIF-1α和SDF-1水平的影响[J]. 河北医药, 2018, 40(12): 1838-1841.</mixed-citation></ref><ref id="hanspub.40833-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">陈丹丹, 帅天姣, 李娟, 张召弟, 孙小航, 朴天华. 糖尿病视网膜病变神经退行性改变的发病机制[J]. 牡丹江医学院学报, 2018, 39(1): 101-104.</mixed-citation></ref><ref id="hanspub.40833-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">袁满, 金玮, 郝昕蕾, 杨安怀. 糖尿病视网膜病变神经血管损伤发病机制的研究进展[J]. 眼科新进展, 2020, 40(9): 885-888.</mixed-citation></ref><ref id="hanspub.40833-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">齐慧君, 黎晓新. 不同分期糖尿病视网膜病变激光治疗预后分析[J]. 中国实用眼科杂志, 2004(10): 801-803.</mixed-citation></ref><ref id="hanspub.40833-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">刘修铎, 陆庆, 徐惠娣, 王倩, 赵婕. 轻型播散性光凝治疗中度非增殖期糖尿病视网膜病变[J]. 国际眼科杂志, 2018, 18(7): 1313-1316.</mixed-citation></ref></ref-list></back></article>